OCULAR HYPERTENSION AFTER INTRAVITREAL INJECTION OF 2-MG TRIAMCINOLONE. Issue 1 (January 2020)
- Record Type:
- Journal Article
- Title:
- OCULAR HYPERTENSION AFTER INTRAVITREAL INJECTION OF 2-MG TRIAMCINOLONE. Issue 1 (January 2020)
- Main Title:
- OCULAR HYPERTENSION AFTER INTRAVITREAL INJECTION OF 2-MG TRIAMCINOLONE
- Authors:
- Storey, Philip P.
Obeid, Anthony
Pancholy, Maitri
Goodman, Jake
Borkar, Durga
Su, Daniel
Regillo, Carl - Abstract:
- Abstract : Purpose: To report the incidence and course of ocular hypertension after intravitreal injection of 2-mg triamcinolone acetonide (IVT). Methods: In a retrospective, consecutive series, all patients receiving 2-mg IVT at a single institution between March 1, 2012, and March 1, 2017, with a minimum of 3-month follow-up were reviewed. Ocular hypertension was defined as an intraocular pressure (IOP) measurement over 24 mmHg at any follow-up visit after IVT. Patients receiving topical, periocular, or intravitreal corticosteroid other than 2-mg IVT were excluded. Results: A total of 106 eyes in 100 patients receiving at least one injection of 2-mg IVT were included. Eyes received an average of 2.9 injections (range 1–17), and average patient follow-up was 15.1 months (range 3.0–52.5 months). A total of 14 eyes (13.2%) in 14 patients developed ocular hypertension after a median of 1.5 injections (range 1–9) with an average peak IOP of 29 mmHg (range 25–38 mmHg). Overall, a total of 11 eyes (10.4%) had an IOP elevation ≥10 mmHg above baseline at any point after first IVT. In all cases of ocular hypertension, IOP was successfully managed with observation or topical IOP-lowering medication alone; no patients required surgical intervention. Conclusion: Ocular hypertension developed in 13.2% of eyes receiving intravitreal injection of 2-mg triamcinolone acetonide. Incidence of ocular hypertension after 2-mg IVT compares favorably with other intravitreally administeredAbstract : Purpose: To report the incidence and course of ocular hypertension after intravitreal injection of 2-mg triamcinolone acetonide (IVT). Methods: In a retrospective, consecutive series, all patients receiving 2-mg IVT at a single institution between March 1, 2012, and March 1, 2017, with a minimum of 3-month follow-up were reviewed. Ocular hypertension was defined as an intraocular pressure (IOP) measurement over 24 mmHg at any follow-up visit after IVT. Patients receiving topical, periocular, or intravitreal corticosteroid other than 2-mg IVT were excluded. Results: A total of 106 eyes in 100 patients receiving at least one injection of 2-mg IVT were included. Eyes received an average of 2.9 injections (range 1–17), and average patient follow-up was 15.1 months (range 3.0–52.5 months). A total of 14 eyes (13.2%) in 14 patients developed ocular hypertension after a median of 1.5 injections (range 1–9) with an average peak IOP of 29 mmHg (range 25–38 mmHg). Overall, a total of 11 eyes (10.4%) had an IOP elevation ≥10 mmHg above baseline at any point after first IVT. In all cases of ocular hypertension, IOP was successfully managed with observation or topical IOP-lowering medication alone; no patients required surgical intervention. Conclusion: Ocular hypertension developed in 13.2% of eyes receiving intravitreal injection of 2-mg triamcinolone acetonide. Incidence of ocular hypertension after 2-mg IVT compares favorably with other intravitreally administered corticosteroids. Abstract : In 106 eyes receiving 2-mg intravitreal triamcinolone, 13.2% of eyes developed intraocular pressure greater than 24 mmHg at any follow-up visit. Ocular hypertension incidence after 2-mg intravitreal triamcinolone compares favorably with other intravitreal steroid agents. … (more)
- Is Part Of:
- Retina. Volume 40:Issue 1(2020)
- Journal:
- Retina
- Issue:
- Volume 40:Issue 1(2020)
- Issue Display:
- Volume 40, Issue 1 (2020)
- Year:
- 2020
- Volume:
- 40
- Issue:
- 1
- Issue Sort Value:
- 2020-0040-0001-0000
- Page Start:
- Page End:
- Publication Date:
- 2020-01
- Subjects:
- intravitreal injection -- ocular hypertension -- steroid -- triamcinolone
Retina -- Diseases -- Periodicals
Retinal Diseases
Vitreous Body
617.735 - Journal URLs:
- http://journals.lww.com/retinajournal/pages/default.aspx ↗
http://journals.lww.com ↗ - DOI:
- 10.1097/IAE.0000000000002361 ↗
- Languages:
- English
- ISSNs:
- 0275-004X
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 7785.510300
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 16968.xml